PT  - JOURNAL ARTICLE
AU  - PASCALE ALICIA HOELL
AU  - KHALED ELSAYAD
AU  - HENDRIK BERSSENBRUEGGE
AU  - DOMINIK HERING
AU  - CHRISTOPHER KITTEL
AU  - JOHANNES KLEINHEINZ
AU  - ANNALEN BLECKMANN
AU  - GEORG EVERS
AU  - EVA WARDELMANN
AU  - CLAUDIA RUDACK
AU  - HANS THEODOR EICH
TI  - Efficacy of Multimodality Approach in Patients With Recurrent Head and Neck Squamous Cell Carcinoma
AID  - 10.21873/anticanres.16272
DP  - 2023 Mar 01
TA  - Anticancer Research
PG  - 1255--1263
VI  - 43
IP  - 3
4099  - http://ar.iiarjournals.org/content/43/3/1255.short
4100  - http://ar.iiarjournals.org/content/43/3/1255.full
SO  - Anticancer Res2023 Mar 01; 43
AB  - Background/Aim: Head and neck squamous cell carcinoma (HNSCC) is characterized by high relapse rates and low survival in comparison to other malignancies. Patients and Methods: Fifty-two patients suffering from recurrent HNSCC were compared, analyzing the impact of different regimes, including surgery, radiotherapy (RT), chemotherapy and immunotherapy on progression-free survival (PFS), overall survival (OS), locoregional control (LRC), and adverse events. Results: The standard RT technique was intensity-modulated radiotherapy (IMRT) in all patients. In the multivariate analysis, higher cumulative RT dose significantly influenced LRC whereas surgery and age significantly impacted PFS and OS. Conclusion: IMRT dose-escalation, as well as surgery, appear beneficial in the treatment of recurrent HNSCC. Moreover, nivolumab and platin-based therapy might be superior agents for systemic therapy in comparison to cetuximab.